Investor Relations

Press Releases

07/12/18
Conformis to Host Second Quarter 2018 Financial Results Webcast on August 1, 2018

BILLERICA, Mass. , July 12, 2018 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS) announced today that it will host a webcast on Wednesday, August 1, 2018 , at 4:30 p.m. Eastern Time to discuss its financial results for the second quarter 2018.  The webcast will be live at:

06/25/18
Peer Reviewed Results: Conformis Patient Specific iTotal CR Achieves Better Rotational Alignment and Tibial Fit Compared to Off-the-Shelf Implants
Manuscript highlights the intraoperative compromises of fit vs. rotation with the legacy off-the-shelf knee implants BILLERICA, Mass., June 25, 2018 (GLOBE NEWSWIRE) -- Conformis Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to
05/02/18
Conformis Reports First Quarter 2018 Financial Results
BILLERICA, Mass. , May 02, 2018 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are customized to fit each patient's unique anatomy,
04/12/18
Conformis to Host First Quarter 2018 Financial Results Conference Call and Webcast on May 2, 2018
BILLERICA, Mass. , April 12, 2018 (GLOBE NEWSWIRE) -- ConforMIS, Inc. (NASDAQ:CFMS) announced today that it will host a conference call on Wednesday, May 2, 2018 , at 4:30 p.m. Eastern Time to discuss its financial results for the first quarter 2018.  To participate in the conference call, please
03/07/18
Four-Year Data from the UK National Joint Registry Highlights High Survivorship in Patients Treated with the Conformis iTotal CR
Data Shows a Low Cumulative Percent Revision of 0.5% for Conformis Patients vs 1.9% for all Total Knee Replacement Patients BILLERICA, Mass. , March 07, 2018 (GLOBE NEWSWIRE) -- Conformis , Inc. (NASDAQ:CFMS), a medical technology company that offers joint replacement implants designed and
03/01/18
Conformis iTotal CR Knee Replacement System Awarded “3A” Rating from the Orthopaedic Data Evaluation Panel in the United Kingdom
Rating highlights positive three-year survivorship following total knee arthroplasty BILLERICA, Mass., March 01, 2018 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), a medical technology company that offers joint replacement implants designed and manufactured to fit and conform to each patient's
02/07/18
ConforMIS Reports Fourth Quarter and the Year Ended 2017 Financial Results; Reiterates 2018 Financial Guidance
BILLERICA, Mass. , Feb. 07, 2018 (GLOBE NEWSWIRE) -- ConforMIS, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are customized to fit each patient's unique anatomy,
01/25/18
ConforMIS Announces Pricing of Public Offering of Common Stock
BILLERICA, Mass. , Jan. 25, 2018 (GLOBE NEWSWIRE) -- ConforMIS ,  Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are customized to fit each patient's unique
01/24/18
ConforMIS Announces Proposed Public Offering of Common Stock
BILLERICA, Mass. , Jan. 24, 2018 (GLOBE NEWSWIRE) -- ConforMIS, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are customized to fit each patient's unique anatomy,
01/08/18
ConforMIS Reports Preliminary Fourth Quarter and Year-End 2017 Revenue Results; Provides 2018 Financial Guidance
ConforMIS to Host Fourth Quarter and the Year Ended 2017 Financial Results Conference Call and Webcast on February 7, 2018 BILLERICA, Mass. , Jan. 08, 2018 (GLOBE NEWSWIRE) -- ConforMIS, Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology
01/04/18
ConforMIS Announces Publication of Results published in the peer-reviewed Journal of Knee Surgery showing 100% of patients treated with iTotal CR achieve mechanical alignment in target range of +/- 3%
BILLERICA, Mass., Jan. 04, 2018 (GLOBE NEWSWIRE) -- ConforMIS, Inc. (NASDAQ:CFMS), a medical technology company that offers joint replacement implants designed and manufactured to fit each patient’s unique anatomy, today announced the publication of a prospective study in The Journal of Knee